FDA Brief Summary Study Would Gauge Patient Perception Of Drug Riskiness
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA publishes draft protocol for trial to assist in finalizing brief summary guidance. The 432-subject trial would gather patients' perceptions of eight advertisements for low- or high-risk products in four medical conditions.
You may also be interested in...
Guidance On Outdoor Promotion Will Formalize "Traditional" Approach – FDA
A draft guidance on outdoor promotion will formalize the Division of Drug Marketing, Advertising & Communications' "traditional" approach to reviewing the advertisements, Director Thomas Abrams said
FDA Finalizing Study Protocols For DTC Ad Brief Summary Research
In the first of three studies, FDA will examine consumer responses to a mock weight-loss drug ad to determine how and why consumers use the brief summary. Research data will be collected in the spring, but a final guidance on the brief summary content and format “will be awhile,” FDA says.
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter